Delving into the Latest Updates on Glutathione/Inosine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Molixan

Target

NGFB

Mechanism

NGFB stimulants(Beta-nerve growth factor stimulants)

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication

Hepatitis BHepatitis C

Inactive Indication

COVID-19Hepatitis C, ChronicRadiation Injuries

Originator Organization

Cellectar Biosciences, Inc.

Active Organization

Sleep Number Labs

Inactive Organization

Cellectar Biosciences, Inc.

Drug Highest PhaseApproved

First Approval Date

RU (10 Sep 2006),

Hepatitis C

Regulation-

Login to view timeline

Structure

Molecular FormulaC10H12N4O5

InChIKeyUGQMRVRMYYASKQ-KQYNXXCUSA-N

CAS Registry58-63-9

View All Structures (2)

Multicenter, prospective, double-blind, placebo-controlled, randomized, parallel-group phase III study.
The study is designed for 2 treatment groups:
Group 1 of the investigational drug - Patients receive standard therapy and the investigational drug.
Group 2 of comparison - Patients receive standard therapy and placebo.

Start Date09 Mar 2021

Sponsor / Collaborator

Pharma VAM

NCT01058512 / CompletedPhase 2

A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin

The purpose of this research study is to find out the effect of the investigational drug NOV-205 on the level of hepatitis C virus in the blood and whether NOV-205 is well-tolerated at different doses when taken by subjects with hepatitis C.

Start Date01 Mar 2010

Sponsor / Collaborator

Cellectar Biosciences, Inc.

NCT00372983 / CompletedPhase 1

A Randomized, Placebo Controlled, Phase 1b Trial to Evaluate the Safety and Pharmacokinetics of NOV-205 in Chronic Viral Hepatitis C Subjects (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin

The purpose of this research trial is to find out whether NOV-205 is well tolerated compared to placebo (salt water) in people with hepatitis C. In addition, this trial will test how NOV-205 is absorbed by your body after single and multiple doses of the trial drug, and it will look for early signs of therapeutic activity (decreases in indicators in the blood for the hepatitis C virus and for liver damage). This is known as pharmacokinetics (PK). NOV-205 is an experimental drug. "Experimental" means that the trial drug is currently being tested and is not approved for sale in the United States by the Food and Drug Administration (FDA). However, NOV-205 has been approved by the Russian Federation for treatment of liver diseases including hepatitis C. Clinical studies in that country showed that subjects treated with NOV-205 alone had decreased indicators in the blood for the hepatitis C virus and for liver damage.

Start Date01 Aug 2006

Sponsor / Collaborator

Cellectar Biosciences, Inc.

100 Clinical Results associated with Glutathione/Inosine

Login to view more data

100 Translational Medicine associated with Glutathione/Inosine

Login to view more data

100 Patents (Medical) associated with Glutathione/Inosine

Login to view more data

18

Literatures (Medical) associated with Glutathione/Inosine

01 Jun 2022·Cell and Tissue Biology

Sigma-1 Receptor Ligands Chlorpromazine and Trifluoperazine Attenuate Ca2+ Responses in Rat Peritoneal Macrophages

Article

Author: Antonov, V G ; Milenina, L S ; Krutetskaya, Z I ; Krutetskaya, N I

Sigma-1 receptors are ubiquitous multifunctional ligand-regulated molecular chaperones in the endoplasmic reticulum membrane with a unique history, structure, and pharmacological profile. Sigma-1 receptors bind ligands of different chemical structure and pharmacological action and modulate a wide range of cellular processes in health and disease, including Ca²⁺ signaling. To elucidate the involvement of sigma-1 receptors in the processes of Ca²⁺ signaling in macrophages we studied the effect of sigma-1 receptor ligands, phenothiazine neuroleptics chlorpromazine and trifluoperazine, on Ca²⁺ responses induced by inhibitors of endoplasmic Ca²⁺-ATPases thapsigargin and cyclopiazonic acid, as well as by disulfide-containing immunomodulators Glutoxim and Molixan in rat peritoneal macrophages. Using Fura-2AM microfluorimetry we showed for the first time that chlorpromazine and trifluoperazine inhibit both phases of Ca²⁺ responses induced by Glutoxim, Molixan, thapsigargin, and cyclopiazonic acid in rat peritoneal macrophages. The data obtained indicate the participation of sigma-1 receptors in a complex signaling cascade caused by Glutoxim or Molixan and leading to an increase in intracellular Ca²⁺ concentration in macrophages. The results also indicate the involvement of sigma-1 receptors in the regulation of store-dependent Ca²⁺entry in macrophages.

01 Jan 2020·Doklady Biochemistry and BiophysicsQ4 · BIOLOGY

Neuroleptic Chlorpromazine Modulates Ca2+ Responses in Macrophages

Q4 · BIOLOGY

Article

Author: Nozdrachev, A D ; Krutetskaya, Z I ; Milenina, L S ; Antonov, V G

Using Fura-2AM microfluorimetry, we have shown for the first time that sigma-1 receptor antagonist neuroleptic chlorpromazine significantly inhibits glutoxim- and molixan-induced Ca²⁺ responses and Ca²⁺ responses induced by endoplasmic reticulum Са²⁺-ATPase inhibitors thapsigargin and cyclopiazonic acid in rat peritoneal macrophages. The results suggest the involvement of sigma-1 receptors in the signaling cascade induced by glutoxim or molixan and leading to intracellular Ca²⁺ concentration increase and in the regulation of store-dependent Ca²⁺ entry in macrophages.

01 Jul 2018·Doklady Biochemistry and Biophysics

Amitriptyline Attenuates Ca2+ Responses Induced by Glutoxim and Molixan in Macrophages

Article

Author: Antonov, V G ; Naumova, A A ; Krutetskaya, Z I ; Milenina, L S ; Nozdrachev, A D ; Butov, S N

Using Fura-2AM microfluorimetry, we have shown for the first time that sigma-1 receptor agonist, tricyclic antidepressant amitriptyline, significantly inhibits glutoxim- and molixan-induced Ca²⁺-responses in rat peritoneal macrophages. The results suggest possible involvement of sigma-1 receptors in the signaling cascade induced by glutoxim or molixan and leading to intracellular Ca²⁺ concentration increase in macrophages.

100 Deals associated with Glutathione/Inosine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	A05A	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hepatitis B	RU	Sleep Number Labs	27 Oct 2006
Hepatitis C	RU	Sleep Number Labs	10 Sep 2006

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	RU	Sleep Number Labs	06 Mar 2021
Hepatitis C, Chronic	Phase 3	US	Cellectar Biosciences, Inc.	01 Mar 2010
Radiation Injuries	Phase 2	US	Cellectar Biosciences, Inc.	-